Cannabinoid Biosynthesis Market Size

  • Report ID: 4142
  • Published Date: Nov 21, 2025
  • Report Format: PDF, PPT

Cannabinoid Biosynthesis Market Outlook:

Cannabinoid Biosynthesis Market size was over USD 25.88 billion in 2025 and is poised to exceed USD 115.16 billion by 2035, growing at over 16.1% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of cannabinoid biosynthesis is estimated at USD 29.63 billion.

The growth of the market can be attributed to the increasing utilization of cannabinoids for medical purposes. Cannabinoids are highly consumed to treat various medical conditions such as, pain management, autoimmune disorders, Alzheimer’s diseases, glaucoma, seizures, HIV/AIDS, and others. The report published by UNAIDS in 2020 demonstrated the fact that about 37.7 million people in the global population were suffering from HIV.

In addition to these, factors that are believed to fuel the market growth of cannabinoid biosynthesis include the higher legal acceptance of cannabinoids in the world. In 2021, Uruguay, Canada, and a few US states has fully legalized cannabis for adult consumption. Moreover, Cannabis cultivation and personal use are now legal in Malta, the first nation in the EU to do so. Adults will be permitted to possess up to seven grams of cannabis and to have a maximum of four plants in their homes. Additionally, the higher sales of cannabis in the world are expected to boost the market growth. US and Canada are the most important market for the sale of cannabis for adult use, moreover, the use of cannabis is expected to grow   in the next 5 years, nig nations, including Israel, Germany, and Australia


Cannabinoid Biosynthesis Market

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of cannabinoid biosynthesis is estimated at USD 29.63 billion.

The global cannabinoid biosynthesis market size was more than USD 25.88 billion in 2025 and is anticipated to grow at a CAGR of over 16.1%, reaching USD 115.16 billion revenue by 2035.

Asia Pacific industry is predicted to hold the largest revenue share by 2035, impelled by rising cases of depression and anxiety expanding the use of medical marijuana.

Key players in the market include Amyris, Inc., Willow Bioscience Inc., Cronos Group, Zymergen Inc., Constellation Brands, Inc., Jazz Pharmaceuticals plc, Canopy Growth Corporation, InMed Pharmaceuticals Inc., Hyasynth Biologicals Inc., Renew Biopharma, Inc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos